Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Harvard Bioscience (HBIO) over the last 9 years, with Q3 2025 value amounting to $536145.0.

  • Harvard Bioscience's Gains from Sales and Divestitures rose 25651.97% to $536145.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $536145.0, marking a year-over-year increase of 25651.97%. This contributed to the annual value of $717119.0 for FY2024, which is 3731.83% down from last year.
  • Harvard Bioscience's Gains from Sales and Divestitures amounted to $536145.0 in Q3 2025, which was up 25651.97% from $442448.0 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Gains from Sales and Divestitures peaked at $1.2 million during Q4 2021, and registered a low of $33979.0 during Q1 2024.
  • For the 5-year period, Harvard Bioscience's Gains from Sales and Divestitures averaged around $447236.7, with its median value being $340395.0 (2021).
  • As far as peak fluctuations go, Harvard Bioscience's Gains from Sales and Divestitures plummeted by 7282.46% in 2024, and later skyrocketed by 62720.5% in 2025.
  • Harvard Bioscience's Gains from Sales and Divestitures (Quarter) stood at $1.2 million in 2021, then crashed by 37.16% to $733611.0 in 2022, then skyrocketed by 55.95% to $1.1 million in 2023, then plummeted by 37.32% to $717119.0 in 2024, then fell by 25.24% to $536145.0 in 2025.
  • Its Gains from Sales and Divestitures was $536145.0 in Q3 2025, compared to $442448.0 in Q2 2025 and $247097.0 in Q1 2025.